BioCentury
ARTICLE | Clinical News

OncoSec reports data from Phase II for ImmunoPulse IL-12 and Keytruda combo

November 30, 2017 11:28 PM UTC

OncoSec Medical Inc. (NASDAQ:ONCS) reported data from the Phase II OMS I-102 trial in 22 melanoma patients predicted to be PD-1 non-responders showing that ImmunoPulse IL-12 (OMS ElectroImmunotherapy, DNA IL-12) plus PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to a best overall response rate (ORR) of 48%. The combo also led to a 6-month progression-free survival (PFS) rate of 62% and an 18-month PFS rate of 57%.

Patients received 200 mg IV Keytruda every 3 weeks and electroporation of ImmunoPulse IL-12 on days 1, 5, and 8 of a 6-week cycle...

BCIQ Target Profiles

Interleukin-12 (IL-12)